Literature DB >> 29600014

Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.

Justin F Gainor1.   

Abstract

Entities:  

Year:  2018        PMID： 29600014      PMCID： PMC5863154          DOI： 10.21037/jtd.2017.12.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  27 in total

1.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

Authors:  Jaemoon Koh; Heounjeong Go; Bhumsuk Keam; Moon-Young Kim; Soo Jeong Nam; Tae Min Kim; Se-Hoon Lee; Hye Sook Min; Young Tae Kim; Dong-Wan Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Mod Pathol       Date:  2015-07-17       Impact factor: 7.842

2.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

3.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Authors:  Nan Chen; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Yanna Tang; Shiyang Kang; Yaxiong Zhang; Xiaobo He; Ting Zhou; Tao Qin; Yan Huang; Xianping Yi; Li Zhang
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

5.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

7.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Authors:  K Haratani; H Hayashi; T Tanaka; H Kaneda; Y Togashi; K Sakai; K Hayashi; S Tomida; Y Chiba; K Yonesaka; Y Nonagase; T Takahama; J Tanizaki; K Tanaka; T Yoshida; K Tanimura; M Takeda; H Yoshioka; T Ishida; T Mitsudomi; K Nishio; K Nakagawa
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.

Authors:  Yanna Tang; Wenfeng Fang; Yaxiong Zhang; Shaodong Hong; Shiyang Kang; Yue Yan; Nan Chen; Jianhua Zhan; Xiaobo He; Tao Qin; Ge Li; Wenyi Tang; Peijian Peng; Li Zhang
Journal:  Oncotarget       Date:  2015-06-10
View more
  1 in total

1.  Immunotherapy strategy of EGFR mutant lung cancer.

Authors:  Shaorong Yu; Delin Liu; Bo Shen; Meiqi Shi; Jifeng Feng
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.